A Phase 3 interventional study of Placebo (for alirocumab) and Alirocumab in Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 83 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-21.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 6th largest by enrollment, is one of 6 that started in 2013, is one of 20 in phase 3, and was the 23rd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 803 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals: none open now, 1 under way, none of them phase 3. Of 12 finished, 10 (83%) have results posted.
Among the 13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2013, is one of 4 in phase 3, and was the 8th registered.
Regeneron Pharmaceuticals’s Hypercholesterolemia studies by the year they started, since 2010.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Regeneron Pharmaceuticals’s 13 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine the efficacy, long-term safety, and tolerability of alirocumab 300 mg every 4 weeks (Q4W), in comparison with placebo, as well as its potential as a starting regimen. The dose regimen of 75 mg every 2 weeks (Q2W), as used in other studies, was added as a calibrator.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The information listed above is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial and not all inclusion/ exclusion criteria are listed.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two subcutaneous (SC) injections of placebo (for alirocumab) Q2W with or without stable statin therapy for 48 weeks.
Drug: Placebo (for alirocumab) · Drug: Statin
One SC injection of each Alirocumab 75 mg and placebo Q2W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.
Drug: Placebo (for alirocumab) · Drug: Alirocumab · Drug: Statin
Two SC injections of Alirocumab 150 mg Q4W alternating with two SC injections of placebo Q4W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.
Drug: Placebo (for alirocumab) · Drug: Alirocumab · Drug: Statin
Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.
Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
Also known as: SAR236553, REGN727, Praluent
Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy
Percent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis
Adjusted LS means and standard errors at Week 24 and at averaged Week 21 to 24 from MMRM including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects without concomitant statin therapy): all randomized subjects who did not receive concomitant statin therapy, with one baseline and at least one post-baseline calculated LDL-C value on- or off-treatment. Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C in Participants Receiving Concomitant Statin Therapy - Intent-to-Treat (ITT Analysis)
Adjusted least squares (LS) means and standard errors at Week 24 and at averaged Week 21 to 24 were obtained from a mixed effect model with repeated measures (MMRM) model to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in this model (ITT analysis). ITT population (subjects with concomitant statin therapy): all randomized subjects who received concomitant statin therapy, with one baseline and at least one post-baseline calculated LDL-C value on- or off-treatment. Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis). Modified ITT (mITT) population (subjects with or without concomitant statin therapy): all randomized and treated subjects who did not receive concomitant statin therapy, with one baseline and at least one post-baseline calculated LDL-C value on-treatment. Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis). Modified ITT (mITT) population (subjects with or without concomitant statin therapy): all randomized and treated subjects who did not receive concomitant statin therapy, with one baseline and at least one post-baseline calculated LDL-C value on-treatment. Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - On-treatment Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - On-treatment Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo B value on- or off-treatment (Apo B ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo B value on- or off-treatment (Apo B ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo B value on- or off-treatment (Apo B ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo B value on- or off-treatment (Apo B ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline non-HDL-C value on- or off-treatment (non-HDL-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline non-HDL-C value on- or off-treatment (non-HDL-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). Subjects of the mITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline non-HDL-C value on-treatment (non-HDL-C mITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). Subjects of the mITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline non-HDL-C value on-treatment (non-HDL-C mITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Total-C value on- or off-treatment (Total-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Total-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Total-C value on- or off-treatment (Total-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo B at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Apo B ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Apo B at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Apo B ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Non-HDL-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Non-HDL-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Total-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Total-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Total-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Total-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL (Without Concomitant Statin Therapy) at Week 24 - ITT Analysis
Very high CV risk: history of documented coronary heart disease (CHD) or CHD risk equivalent. High CV risk: calculated 10-year fatal CVD risk score ≥5%, moderate chronic kidney disease, type 1/type 2 diabetes mellitus (DM) without target organ damage, or heFH not meeting definition of very high risk. Moderate CV risk: calculated 10-year fatal CVD risk score ≥1 \&\<5%. CHD risk equivalent: peripheral arterial disease, ischemic stroke, transient ischemic attack, abdominal aortic aneurysm, carotid artery(CA)occlusion\>50%, carotid endarterectomy/CA stent procedure, renal artery stenosis/stent procedure, type 1/type 2 DM with target organ damage. Adjusted percentages at Week 24 obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment included in imputation model. ITT population (subjects with or without concomitant statin therapy).
Time frame: Up to Week 24
Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (With Concomitant Statin Therapy) at Week 24 - ITT Analysis
Very high CV risk: history of documented coronary heart disease (CHD) or CHD risk equivalent. High CV risk: calculated 10-year fatal CVD risk score ≥5%, moderate chronic kidney disease, type 1/type 2 diabetes mellitus (DM) without target organ damage, or heFH not meeting definition of very high risk. Moderate CV risk: calculated 10-year fatal CVD risk score ≥1 \&\<5%. CHD risk equivalent: peripheral arterial disease, ischemic stroke, transient ischemic attack, abdominal aortic aneurysm, carotid artery(CA)occlusion\>50%, carotid endarterectomy/CA stent procedure, renal artery stenosis/stent procedure, type 1/type 2 DM with target organ damage. Adjusted percentages at Week 24 obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment included in imputation model. ITT population (subjects with or without concomitant statin therapy).
Time frame: Up to Week 24
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL(2.59 mmol/L) (Without Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis
Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: Up to Week 24
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL(1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL(2.59 mmol/L) (With Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis
Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: Up to Week 24
Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: Up to Week 24
Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: Up to Week 24
Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: Up to Week 24
Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: Up to Week 24
Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment were included in the imputation model. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment were included in the imputation model. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline HDL-C value on- or off-treatment (HDL-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline HDL-C value on- or off-treatment (HDL-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm
Time frame: From Baseline to Week 24
Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. HDL-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. HDL-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (subjects with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo A1 value on- or off-treatment (Apo A1 ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (subjects with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo A1 value on- or off-treatment (Apo A1 ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Apo A1 ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Apo A1 ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
Time frame: From Baseline to Week 12
The study was conducted at 97 sites in 8 countries. A total of 1491 subjects were screened between September 2013 and April 2014, 688 of whom were screen failures. Screen failures were mainly due to inclusion criteria not met.
| Milestone | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|---|---|---|
| Started | 157 | 78 | 312 | 73 | 37 | 146 |
| Treated | 157 | 78 | 312 | 72 | 37 | 146 |
| Completed 24 weeks treatment period | 137 | 68 | 285 | 58 | 31 | 120 |
| Completed | 129 | 65 | 272 | 53 | 29 | 105 |
| Not completed | 28 | 13 | 40 | 20 | 8 | 41 |
| Withdrew: Participant moved | 2 | 0 | 1 | 1 | 0 | 3 |
| Withdrew: Physician decision | 0 | 2 | 1 | 1 | 0 | 0 |
| Withdrew: Other than specified | 2 | 3 | 5 | 12 | 4 | 11 |
| Withdrew: Adverse event | 13 | 4 | 17 | 4 | 3 | 14 |
| Withdrew: Poor compliance to protocol | 5 | 3 | 8 | 0 | 1 | 6 |
| Withdrew: Randomized and not treated | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 1 | 8 | 1 | 0 | 5 |
| Withdrew: Related to study drug administration | 0 | 0 | 0 | 0 | 0 | 2 |
Adjusted LS means and standard errors at Week 24 and at averaged Week 21 to 24 from MMRM including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects without concomitant statin therapy): all randomized subjects who did not receive concomitant statin therapy, with one baseline and at least one post-baseline calculated LDL-C value on- or off-treatment. Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| At Week 24 | -0.3 ± 2.7 | -50.2 ± 3.7 | -52.7 ± 1.9 |
| At averaged Week 21 to 24 | -1.6 ± 2.6 | -54 ± 3.6 | -56.9 ± 1.8 |
Adjusted least squares (LS) means and standard errors at Week 24 and at averaged Week 21 to 24 were obtained from a mixed effect model with repeated measures (MMRM) model to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in this model (ITT analysis). ITT population (subjects with concomitant statin therapy): all randomized subjects who received concomitant statin therapy, with one baseline and at least one post-baseline calculated LDL-C value on- or off-treatment. Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| At Week 24 | -0.1 ± 2.3 | -51.6 ± 3.3 | -58.8 ± 1.6 |
| At averaged Week 21 to 24 | 0.8 ± 2.0 | -57.9 ± 2.8 | -65.8 ± 1.4 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis). Modified ITT (mITT) population (subjects with or without concomitant statin therapy): all randomized and treated subjects who did not receive concomitant statin therapy, with one baseline and at least one post-baseline calculated LDL-C value on-treatment. Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis | -0.4 ± 2.0 | -54.6 ± 2.8 | -59.4 ± 1.4 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis). Modified ITT (mITT) population (subjects with or without concomitant statin therapy): all randomized and treated subjects who did not receive concomitant statin therapy, with one baseline and at least one post-baseline calculated LDL-C value on-treatment. Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis | -0.3 ± 2.1 | -55.1 ± 3.0 | -62.3 ± 1.5 |
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis | 0.3 ± 2.1 | -51.8 ± 2.9 | -58.4 ± 1.4 |
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis | 1.1 ± 2.2 | -45.3 ± 3.1 | -55.3 ± 1.5 |
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - On-treatment Analysis | -0.5 ± 2.0 | -53.9 ± 2.7 | -60.0 ± 1.4 |
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - On-treatment Analysis | 1.4 ± 1.9 | -47.3 ± 2.8 | -58.0 ± 1.4 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo B value on- or off-treatment (Apo B ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis | -0.7 ± 2.3 | -39.0 ± 3.3 | -40.2 ± 1.6 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo B value on- or off-treatment (Apo B ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis | 3.1 ± 1.8 | -36.7 ± 2.6 | -45.1 ± 1.3 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo B value on- or off-treatment (Apo B ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Apo B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis | -0.3 ± 2.0 | -42.0 ± 2.7 | -44.8 ± 1.4 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo B value on- or off-treatment (Apo B ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis | 3.1 ± 1.7 | -38.3 ± 2.5 | -47.2 ± 1.2 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline non-HDL-C value on- or off-treatment (non-HDL-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis | -0.3 ± 2.5 | -43.6 ± 3.4 | -43.3 ± 1.7 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline non-HDL-C value on- or off-treatment (non-HDL-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis | 0.3 ± 1.9 | -41.6 ± 2.7 | -49.7 ± 1.3 |
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). Subjects of the mITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline non-HDL-C value on-treatment (non-HDL-C mITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis | 0.1 ± 2.1 | -47.2 ± 2.8 | -48.9 ± 1.4 |
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). Subjects of the mITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline non-HDL-C value on-treatment (non-HDL-C mITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis | 0.2 ± 1.8 | -44.4 ± 2.5 | -52.6 ± 1.2 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Total-C value on- or off-treatment (Total-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis | -1.9 ± 1.9 | -32.5 ± 2.6 | -33.3 ± 1.3 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Total-C value on- or off-treatment (Total-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Total-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis | -0.8 ± 1.4 | -30.0 ± 2.0 | -35.8 ± 1.0 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Apo B ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Apo B at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis | -2.3 ± 1.7 | -40.8 ± 2.5 | -46.4 ± 1.3 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Apo B ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Apo B at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis | 3.6 ± 1.8 | -33.0 ± 2.5 | -41.2 ± 1.3 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Non-HDL-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis | -0.4 ± 1.8 | -45.8 ± 2.5 | -49.9 ± 1.3 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Non-HDL-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis | 0.6 ± 1.9 | -37.4 ± 2.7 | -46.5 ± 1.3 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Total-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Total-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis | -1.0 ± 1.4 | -33.4 ± 2.0 | -37.4 ± 1.0 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Total-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Total-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis | -0.1 ± 1.3 | -26.5 ± 1.9 | -32.9 ± 1.0 |
Very high CV risk: history of documented coronary heart disease (CHD) or CHD risk equivalent. High CV risk: calculated 10-year fatal CVD risk score ≥5%, moderate chronic kidney disease, type 1/type 2 diabetes mellitus (DM) without target organ damage, or heFH not meeting definition of very high risk. Moderate CV risk: calculated 10-year fatal CVD risk score ≥1 \&\<5%. CHD risk equivalent: peripheral arterial disease, ischemic stroke, transient ischemic attack, abdominal aortic aneurysm, carotid artery(CA)occlusion\>50%, carotid endarterectomy/CA stent procedure, renal artery stenosis/stent procedure, type 1/type 2 DM with target organ damage. Adjusted percentages at Week 24 obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment included in imputation model. ITT population (subjects with or without concomitant statin therapy).
| percentage of participants | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL (Without Concomitant Statin Therapy) at Week 24 - ITT Analysis | 9.4 | 84.9 | 78.9 |
Very high CV risk: history of documented coronary heart disease (CHD) or CHD risk equivalent. High CV risk: calculated 10-year fatal CVD risk score ≥5%, moderate chronic kidney disease, type 1/type 2 diabetes mellitus (DM) without target organ damage, or heFH not meeting definition of very high risk. Moderate CV risk: calculated 10-year fatal CVD risk score ≥1 \&\<5%. CHD risk equivalent: peripheral arterial disease, ischemic stroke, transient ischemic attack, abdominal aortic aneurysm, carotid artery(CA)occlusion\>50%, carotid endarterectomy/CA stent procedure, renal artery stenosis/stent procedure, type 1/type 2 DM with target organ damage. Adjusted percentages at Week 24 obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment included in imputation model. ITT population (subjects with or without concomitant statin therapy).
| percentage of participants | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (With Concomitant Statin Therapy) at Week 24 - ITT Analysis | 22.2 | 82.5 | 85.2 |
Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percentage of participants | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL(2.59 mmol/L) (Without Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis | 11.3 | 93.0 | 88.6 |
Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percentage of participants | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL(1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL(2.59 mmol/L) (With Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis | 22.5 | 86.4 | 89.5 |
Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percentage of participants | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis | 3.3 | 57.7 | 62.0 |
Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percentage of participants | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis | 10.9 | 74.4 | 80.4 |
Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percentage of participants | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis | 2.1 | 61.7 | 70.4 |
Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percentage of participants | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis | 10.8 | 77.4 | 84.8 |
Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment were included in the imputation model. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis | 6.4 ± 3.4 | -14.0 ± 4.8 | -21.3 ± 2.4 |
Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment were included in the imputation model. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis | 9.8 ± 2.4 | -16.9 ± 3.3 | -19.3 ± 1.6 |
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis | -5.5 ± 3.3 | -26.9 ± 4.7 | -28.9 ± 2.3 |
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis | 7.0 ± 2.3 | -12.4 ± 3.2 | -19.6 ± 1.6 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline HDL-C value on- or off-treatment (HDL-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis | -5.3 ± 1.7 | -0.1 ± 2.4 | 2.5 ± 1.2 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline HDL-C value on- or off-treatment (HDL-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis | -1.5 ± 1.2 | 6.0 ± 1.7 | 3.6 ± 0.8 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. HDL-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis | -0.9 ± 1.6 | 2.5 ± 2.2 | 6.0 ± 1.1 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. HDL-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis | 0.4 ± 1.2 | 7.6 ± 1.8 | 5.7 ± 0.9 |
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis | -1.5 ± 3.4 | -9.8 ± 4.9 | -13.4 ± 2.5 |
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis | -0.1 ± 2.4 | -6.7 ± 3.3 | -15.2 ± 1.6 |
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis | 1.8 ± 3.2 | -18.3 ± 4.6 | -12.3 ± 2.3 |
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis | 0.5 ± 2.4 | -7.3 ± 3.5 | -13.1 ± 1.7 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (subjects with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo A1 value on- or off-treatment (Apo A1 ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis | -1.4 ± 1.3 | 3.1 ± 1.9 | 5.2 ± 0.9 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (subjects with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo A1 value on- or off-treatment (Apo A1 ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis | 2.9 ± 1.0 | 6.5 ± 1.4 | 5.5 ± 0.7 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Apo A1 ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis | -1.8 ± 1.3 | 2.4 ± 1.8 | 4.6 ± 0.9 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Apo A1 ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.
| percent change | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin |
|---|---|---|---|
| Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis | 2.7 ± 1.0 | 6.1 ± 1.4 | 6.0 ± 0.7 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 56 post-treatment follow-up visit) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Q2W | — | 33/229 (14.4%) | 118/229 (51.5%) |
| Alirocumab 75 mg Q2W/Up 150 mg Q2W | — | 13/115 (11.3%) | 55/115 (47.8%) |
| Alirocumab 300 mg Q4W/Up 150 mg Q2W | — | 53/458 (11.6%) | 229/458 (50%) |
| Event | Placebo Q2W | Alirocumab 75 mg Q2W/Up 150 mg Q2W | Alirocumab 300 mg Q4W/Up 150 mg Q2W |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/229 | 2/115 | 1/458 |
| Myocardial infarctionCardiac disorders | 3/229 | 0/115 | 1/458 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 3/229 | 0/115 | 3/458 |
| Angina unstableCardiac disorders | 2/229 | 0/115 | 2/458 |
| Non-Cardiac chest painGeneral disorders | 1/229 | 1/115 | 4/458 |
| Angina pectorisCardiac disorders | 1/229 | 1/115 | 1/458 |
| Cardiac failure chronicCardiac disorders | 0/229 | 1/115 | 0/458 |
| Ischaemic cardiomyopathyCardiac disorders | 0/229 | 1/115 | 0/458 |
| Mitral valve incompetenceCardiac disorders | 0/229 | 1/115 | 0/458 |
| Ventricular tachycardiaCardiac disorders | 0/229 | 1/115 | 0/458 |
| Event | Placebo Q2W | Alirocumab 75 mg Q2W/Up 150 mg Q2W | Alirocumab 300 mg Q4W/Up 150 mg Q2W |
|---|---|---|---|
| Injection site reactionGeneral disorders | 16/229 | 10/115 | 74/458 |
| Upper respiratory tract infectionInfections and infestations | 18/229 | 8/115 | 41/458 |
| NasopharyngitisInfections and infestations | 18/229 | 10/115 | 39/458 |
| DiarrhoeaGastrointestinal disorders | 17/229 | 4/115 | 25/458 |
| NauseaGastrointestinal disorders | 15/229 | 7/115 | 19/458 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 15/229 | 7/115 | 29/458 |
| Back painMusculoskeletal and connective tissue disorders | 14/229 | 3/115 | 29/458 |
| HeadacheNervous system disorders | 13/229 | 6/115 | 29/458 |
| SinusitisInfections and infestations | 11/229 | 4/115 | 28/458 |
| Urinary tract infectionInfections and infestations | 10/229 | 7/115 | 28/458 |
All randomized population regardless of concomitant statin therapy.
| Age, Continuous(years) | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin | Total |
|---|---|---|---|---|---|---|---|
| Mean | 61.6 ± 9.7 | 60.7 ± 9.1 | 61.6 ± 10 | 59.4 ± 10.2 | 59.3 ± 11.3 | 59.2 ± 10.8 | 60.8 ± 10.1 |
| Sex: Female, Male(Participants) | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin | Total |
|---|---|---|---|---|---|---|---|
| Female | 56 | 27 | 122 | 33 | 23 | 80 | 341 |
| Male | 101 | 51 | 190 | 40 | 14 | 66 | 462 |
| Calculated LDL-C in mg/dL(mg/dL) | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin | Total |
|---|---|---|---|---|---|---|---|
| Mean | 112.1 ± 37.3 | 114.9 ± 36 | 112.4 ± 32.8 | 131 ± 30.4 | 148.4 ± 36.8 | 146.1 ± 33.5 | 122.1 ± 36.9 |
| Calculated LDL-C in mmol/L(mmol/L) | Placebo Q2W With Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin | Placebo Q2W Without Concomitant Statin | Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin | Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin | Total |
|---|---|---|---|---|---|---|---|
| Mean | 2.903 ± 0.965 | 2.977 ± 0.933 | 2.912 ± 0.85 | 3.392 ± 0.787 | 3.842 ± 0.953 | 3.785 ± 0.868 | 3.162 ± 0.956 |
The record gives a start of Sep 2013, a primary completion of Sep 2014 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 2 years 6 months after primary completion. A results delay was requested in Jan 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab